FDA Warning Letter for inadequate Batch Record Review
The U.S. Food and Drug Administration (FDA) recently posted a Warning Letter for a Chinese API manufacturer criticising the quality unit for not exercising its responsibility adequately.
For example, batch production records
- "contained blank or partially completed manufacturing data"
- "lacked dates and signatures for verification"
- "contained sticky notes from the quality assurance department directing operators to enter manufacturing data"
- were not approved by the quality unit
Also other documents like, for example, cleaning records and equipment use logs were found "without dates and signatures for verification, or with pages or spaces intentionally left blank for documentation at a later time".
As a conclusion, FDA stated that these "significant inspection findings indicate that your quality unit is not fully exercising its authority and/or responsibilities". And FDA placed the company on Import Alert.
Source: FDA Warning Letter to Qinhuangdao Zizhu Pharmaceutical.
Related GMP News
25.06.2025Is Knowledge Management a Part of the Pharmaceutical Quality System?
11.06.2025Swissmedic differentiates GMP Scope for Manufacturing and Preparation for Administration
28.05.2025A View on the EU Critical Medicines Act to secure Pharma Supply Chains
20.05.2025Summary Data on Registration and Listing of Cosmetic Facilities and Products
07.05.2025FDA is extending its Quality Management Maturity Programme
30.04.2025FDA Warning Letter on missing Audit Trails and Raw Data Review